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Objective: The aim of this study was to analyze the immunohistochemical expression of Skp2 protein in 38 oral 
nevi and 11 primary oral melanomas. 
Study Design: Expression of this ubiquitin protein was evaluated by immunohistochemistry in 49 oral melano-
cytic lesions, including 38 intramucosal nevi and 11 primary oral melanomas. The labeling index (LI) was as-
sessed considering the percentage of cells expressing nuclear positivity out of the total number of cells, counting 
1000 cells per slide.              
Results: Skp2 protein was rarely expressed in intramucosal nevi, in contrast to oral melanomas, which showed 
high levels of this protein. 
Conclusion: These results indicate that Skp2 protein may play a role in the development and progression of oral 
melanomas, and it also could be useful as an immunohistochemical marker for differential diagnosis of oral be-
nign and malignant melanocytic lesions.  
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Introduction
The transformation of melanocytes to melanoma cells 
involves abnormal cell proliferation associated with 
alterations in the cell cycle regulatory mechanisms (1). 
Cell cycle progression requires the coordinated per-
formance of a series of regulating molecules that or-
chestrate cycle transitions through either mitogenic or 
antiproliferative signals (2). Disruption of the mecha-
nisms involved in protein synthesis and degradation can 
lead to abnormal cell proliferation and oncogenesis (3). 
It is well known that the ubiquitin proteasomal pathway 
plays a paramount role in the degradation of short-lived 
regulatory proteins involved in the cell cycle (2). 
The ubiquitin ligase complex formed by Skp2, Skp1 and 
cullin F-box (SCFSKP2) is required for direct ubiquina-
tion and proteolysis of p27 and other cell cycle regulato-
ry proteins such as cyclin E and the transcription factor 
E2F-1, performing an S phase promoting function (4,5). 
Overexpression of Skp2 results in cell cycle progression 
and eventually neoplastic transformation, as its levels 
correlates with histologic grade, clinical aggressiveness 
and prognosis in lymphomas, oral squamous cell carci-
noma, prostate adenocarcinoma, ovarian adenocarcino-
ma, soft tissue sarcomas, gastric carcinomas and breast 
cancers (6-8). 
Recent studies have shown that Skp2 protein expression 
is implicated in cutaneous melanoma progression, and 
it may also serve as a biomarker to detect pre-malignant 
and malignant lesions (3,9). The immunohistochemi-
cal expression of Skp2 protein has not yet been studied 
in oral benign and malignant melanocytic lesions, and 
therefore, this is the objective of this study. 
Material and Methods
Formalin-fixed, paraffin-embedded tissue blocks were 
obtained from 49 oral melanocytic lesions, correspond-
ing to 38 intramucosal nevi and 11 primary oral melano-
mas. Intramucosal nevi patients included 30 women and 
8 men, aged 16 to 67 years, 13 located in hard palate, 11 
in the buccal mucosa, 10 in the gingiva, and 4 the site 
was not specified. Cases of primary oral melanomas cor-
responded to 8 women and 3 men, aged 23 to 86 years, 
6 located in hard palate, 3 involving the hard palate and 
upper gingiva, and 2 the upper gingiva. Diagnosis of 
melanoma was confirmed by clinical and histological 
characteristics, excluding the presence of melanoma at 
other anatomical sites and consequently the possibility 
of oral metastasis. Melanomas were histologically clas-
sified according to Prasad et al. (10) and all cases cor-
responded to level III (very deep invasion). 
For immunohistochemical staining, 3 µm thick sec-
tions mounted on silane-coated glass slides were used. 
Briefly, the sections were deparaffinized and rehydrated 
in graded ethanol solutions. After antigen retrieval with 
EDTA/Tris buffer (pH 9.0) in a microwave oven (1380 
W; Panasonic, São Paulo, Brazil), endogenous peroxi-
dase activity was blocked with 20% H2O2 using five 
cycles of 5 minutes each. Overnight incubation with 
the primary antibody Skp2 (Santa Cruz Biotechnology, 
Santa Cruz, California USA) diluted in BSA (bovine 
serum albumin-1:200) was followed by incubation with 
the secondary antibody conjugated with polymer dex-
tran marked with peroxidase (Dako EnVision Labeled 
Polymer; Dako, Glostrup, Denmark). Reactions were 
developed with a solution containing 0.6 mg/ml 3,3′-
diaminobenzidine tetrahydrochloride (DAB, Sigma, St. 
Louis, MO, USA) and 0.01% H2O2 and counterstained 
with Carazzi’s hematoxylin. Positive and negative con-
trols were included in all reactions. Only nuclear stain-
ing was considered positive. As we used DAB as the de-
veloper, the reactions could be confounded by melanin 
in the cytoplasm of benign and malignant melanocytes, 
but this was not a problem for Skp2 because it is a nu-
clear marker.
The labeling index (LI) was assessed considering the 
percentage of cells expressing nuclear positivity out of 
the total number of cells, counting 1000 cells per slide. 
The slides were examined under a Leica DMR micro-
scope and images were captured using a Leica digital 
camera (Leica Microsystems Inc., 1700 Leider Lane, 
Buffalo Grove, IL, USA). Immunoreactive cells were 
counted randomly with a minimum of 10 high-power 
fields (x400), with the help of an image computer ana-
lyzer (ImageJ, Image Processing and Analysis in Java).
Results
The epithelial cells of the normal oral mucosa in nevi 
and melanomas showed Skp2 protein positivity restrict-
ed to the nuclei of basal epithelial cells, together with 
some cells in the immediate suprabasal layers, serv-
ing as an internal positive control. The most superficial 
cells of the epithelium were negative in all cases (Fig. 
1). Skp2 protein was rarely expressed in intramucosal 
nevi, with LI lower than 1% in all cases. The location of 
Skp2 expression was heterogeneous, not involving spe-
cific areas of nevus cells nests (Fig. 1). In primary oral 
melanomas, 17.5% (range: 8.7% to 36.5%) of malignant 
cells expressed Skp2 in the nucleus, mainly on the su-
perficial central compartment of the tumor rather than 
in the tumor margins (Fig. 2).
Discussion
Melanoma is known to exhibit aberrant expression of 
cell-cycle-regulating proteins. The F-box protein Skp2 
is a component of the ubiquitin protein ligases that play 
a critical role in the regulation of G to S phase progres-
sion (6). Cell cycle progression is driven by an increase 
of Skp2, which is responsible for ubiquination of some 
cell cycle proteins such as cyclin E and p27 (4,5). In 
this study we evaluated the immunohistochemical ex-
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pression of Skp2 protein in 38 intramucosal nevi and 
11 primary oral melanomas, as there are no data on im-
munohistochemical expression of Skp2 in oral melano-
cytic lesions and only 4 reports consider its relevance in 
cutaneous melanocytic lesions (3,9,11,12).
We found low expression of nuclear Skp2 in oral nevi 
compared to melanomas, confirming an oncogenic po-
tential of Skp2. This is also in accordance with litera-
ture reports of negative or weak expression of Skp2 pro-
tein in benign cutaneous melanocytic lesions and high 
levels in melanomas (3,9,11-13). Li et al. (3) reported a 
progressive and significant increase in the nuclear ex-
pression of Skp2, moving from melanocytic nevi to 
melanoma in situ, primary cutaneous melanoma and 
metastatic melanoma respectively, suggesting that this 
protein is implicated in melanoma progression. High 
levels of Skp2 have also been shown in a variety of 
cancers such as prostate (14), oral squamous carcinoma 
(7,15) and colorectal carcinomas (16). Also attesting the 
importance of Skp2 in tumor development, there is a re-
port using transgenic mouse model where Skp2 overex-
pression induced prostatic hyperplasia, dysplasia, and 
low-grade carcinoma (17).
The present study did not consider the relation between 
expression levels of Skp2 protein with stage and prognosis 
of oral melanomas, but it is well known that oral melano-
mas have a poor prognosis and all our cases showed deep 
invasion. Nevertheless, it is has been shown that Skp2 nu-
clear protein expression have prognostic impact in some 
human cancers such as squamous cell carcinoma (7). 
Nevertheless, in cutaneous melanomas results are con-
troversial, as increased expression of nuclear Skp2 have 
been correlated either with reduced survival time (9), or 
that it was not associated with prognosis (3).
In conclusion, our data suggest that increased Skp2 ex-
pression plays a role in the development of oral melano-
mas. Overexpression of Skp2 may represent an impor-
tant mechanism in abrogating the cell-cycle inhibitory 
and apoptotic effects of some cell cycle proteins such 
as of p27 and cyclin E, increasing their degradation, 
thus contributing to the expansion of malignant clones 
of melanocytes and tumor progression. Besides to be 
involved in the pathogenesis of oral melanomas, Skp2 
could also be useful as an additional diagnostic marker 
for differential diagnosis of oral benign and malignant 
melanocytic lesions. 
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